This summer saw the first deadline for the new SME Instrument, and the evaluation feedback from the European Commission could be a wake-up call for small companies across Europe.

“External innovation” is one of the pharmaceutical industry’s solutions for overcoming patent cliffs and gaps in innovation. It’s based on the insight that the majority of innovations in this sector do not have their origin in Big Pharma, but come from academia and small biotech companies.